• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}

    • Login for full access to training, resources and events for healthcare professionals.

      Not Registered? It's simple and takes less than 2 minutes, Register now

      You must be registered to see the full details of our expert-led learning, events, webinars and resources.

      PBS Information


      BOTOX®: Section 100 Authority required (STREAMLINED). BOTOX® injection is listed on the PBS for Spasmodic Torticollis (Cervical Dystonia); Focal Spasticity due to Juvenile Cerebral Palsy; Moderate to Severe Spasticity of the Upper Limb following an acute event; Moderate to Severe Spasticity of the Lower Limb following an acute event; Blepharospasm or Hemifacial Spasm; Severe Primary Axillary Hyperhidrosis; Neurogenic Detrusor Overactivity; Prevention of Chronic Migraine; Overactive Bladder. Refer to PBS Schedule for full authority information.

      Please review the full Product Information (PI) before prescribing, available below.

      New Zealand

      BOTOX® (Botulinum toxin type A) is a Prescription Medicine. Before prescribing Botox please refer to the data sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The Data Sheet is available on request from AbbVie by phoning 0800 659 912 or on the Medsafe website.

      BOTOX® injection is available under Section H of the PHARMAC Pharmaceutical Schedule.
      No restrictions apply.

      BOTOX® is indicated for: the treatment of overactive bladder with symptoms of urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication; urinary incontinence due to neurogenic detrusor overactivity (eg. spinal cord injury or multiple sclerosis); in adults who have an inadequate response to or are intolerant of an anticholinergic medication; prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month with headaches lasting 4 hours a day or longer, of which 8 days are with migraine); strabismus; blepharospasm associated with dystonia, including benign essential blepharospasm & VIIth nerve disorders; cervical dystonia (spasmodic torticollis); focal spasticity in children 2 years & older; primary hyperhidrosis of the axillae; and focal spasticity in adults.

      NZ-BTX-230007. Date of Preparation: April 2023.